Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 13 bp deletion in exon 2
Product details:
We will provide viable cells that proliferate on revival.
Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-MACROH2A1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MH2A1 also known as macroH2A1 is a histone variant with a distinguished structure characterized by an extended C-terminal macro domain. It has a molecular mass of approximately 42-45 kDa. This histone variant is widely expressed across various tissues showing particularly high levels in differentiated cells. mH2A1 incorporates into chromatin impacting nucleosome stability and chromatin dynamics. Researchers have also identified an isoform known as H2AFY which further highlights the structural complexity and versatile roles of mH2A1 in cellular regulation.
Biological function summary
MH2A1 plays significant roles in chromatin remodeling and gene expression regulation. It is part of the nucleosome replacing canonical histone H2A and influencing the accessibility of chromatin to transcriptional machinery. Through this function mH2A1 can repress or activate gene expression depending on cellular context and interacting partners. Its incorporation into chromatin is associated with the silencing of certain genomic regions such as inactive X chromosome in females with potential implications for epigenetic modifications and cellular differentiation.
Pathways
MH2A1 is notably involved in pathways regulating chromatin organization and cell differentiation. It plays a role in the Polycomb Repressive Complex 2 (PRC2) pathway affecting histone methylation and gene silencing. Furthermore mH2A1 interacts with proteins like EZH2 in PRC2 which carry out methylation at histone H3 on lysine 27. These interactions highlight mH2A1's involvement in maintaining repressive chromatin states and controlling gene expression patterns important for normal cell function.
MH2A1 is connected with cancer and metabolic diseases. Its altered expression has been observed in various cancers where it might impact tumor progression by modulating genes linked to proliferation and differentiation. mH2A1 influences pathways shared with proteins like BRAC1 that are involved in DNA repair processes. Additionally changes in mH2A1 expression are linked to metabolic disorders especially those affecting lipid metabolism and insulin responses suggesting its potential role in regulating metabolic pathways and influencing disease progression.
